Payday lenders took in $2.4 billion in fees from cash-strapped consumers in a single year, a report from the Center for ...

Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Charles River (CRL) to $184 from $220 and keeps an Equal Weight rating ...

Kirby McInerney LLP Urges Investors in Applied Therapeutics, Inc. (APLT) to Inquire About Their Rights in Class Action Lawsuit. Tweet ...

Charles River Laboratories International, Inc. CRL is scheduled to report fourth-quarter 2024 results on Feb.19, before ...

In a report released on February 1, Casey Woodring from J.P. Morgan maintained a Hold rating on Charles River Labs (CRL – Research Report), ...

Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, ...

Complete response letter hurdles overcome and U.S. FDA clearance in hand, Axsome Therapeutics Inc. will disclose pricing in about four months, closer to the launch of Symbravo to treat adult migraine ...

Atomi Financial Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Crossmark Global Holdings Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...

6 analysts have shared their evaluations of Charles River CRL during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International (NYSE:CRL) from Outperform to Market Perform. Analyst Price Forecast ...